• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

    2/19/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email

    2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year

    Projecting 2025 Total Revenue Growth of 17-24% at CER

    Anticipate Achieving Positive GAAP Net Income During H2 2025

    Conference Call and Webcast Today at 8:30 a.m. ET

    PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024.

    "We closed 2024 beating expectations with exceptional revenue growth of 33 percent. With our portfolio and global rare disease capabilities, we have a clear path to deliver continued revenue growth and accelerating profitability in 2025 and the years ahead. We have firmly established Amicus as a unique biotechnology company: two growing medicines with long runways, a leverageable infrastructure with patients at the center, and the financial strength to continue to build the business and our leadership in rare diseases," said Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc.

    Corporate Highlights:

    • Total revenues for the full-year 2024 were $528.3 million, reflecting operational growth measured at constant exchange rates (CER)1 of 33% and a small currency impact of $1.1 million or 1%. Fourth quarter total revenues were $149.7 million, up 30% as reported and at CER. For the full year 2025, the Company provides total revenue growth guidance of +17% to +24% on a constant currency basis (CER)1.

    (in thousands)Three Months Ended

    December 31,
     Year over Year %

    Growth
     Twelve Months Ended

    December 31,
     Year over Year %

    Growth
     2024 2023 Reported at CER1  2024  2023 Reported at CER1
    Galafold®127,497 106,601 20% 20%  458,054  387,777 18%  19%
    Pombiliti® + Opfolda®22,209 8,481 162% 161%  70,241  11,579 507%  504%
    Net Product Revenues149,706 115,082 30% 30% $528,295 $399,356 32%  33%


    • Galafold (migalastat) net product sales for the full-year 2024 were $458.1 million, representing a year-over-year increase of 18%, or 19% at CER. Fourth quarter net product sales were $127.5 million. At the end of 2024, there were ~2,730 people living with Fabry disease on Galafold following a year of increased demand. For the full year 2025, the Company provides revenue growth guidance for Galafold of +10% to +15% on a constant currency basis (CER)1.
    • Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) net product sales for the full-year 2024 were $70.2 million. Fourth quarter net product sales were $22.2 million. Following a successful commercial launch in the U.S., Germany, Austria, Spain and the U.K., there were ~220 patients treated or scheduled with commercial product as of the end of 2024. For the full year 2025, the Company provides revenue growth guidance for Pombiliti + Opfolda of +65% to +85% on a constant currency basis (CER)1.
    • Multiple Pombiliti + Opfolda pricing and reimbursement agreements recently achieved. Agreements completed in late 2024 and early 2025 include Italy, Sweden, Switzerland, Czech Republic and most recently the Netherlands. First commercial patients from these countries are anticipated to begin treatment over the first half of 2025. Additionally, Pombiliti + Opfolda received regulatory approval in Australia and the Company anticipates new regulatory decisions in Canada and Japan in 2025 as well as additional reimbursement agreements throughout the year.
    • Amicus is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The Company anticipates continuing to grow its current commercial business with Galafold and Pombiliti + Opfolda resulting in strong total revenue growth.
    • Total GAAP operating expenses of $450.5 million for the full year 2024 increased by 2.6% as compared to $439.2 million for the full year 2023. Total non-GAAP operating expenses2 were up 1.8% to $347.8 million for the full year 2024 as compared to $341.6 million for the full year 2023. For the full year 2025, the Company provides non-GAAP operating expense4 guidance range of $350 million to $370 million.
    • GAAP net loss was $56.1 million, or $0.18 per share basic and diluted, for the full year 2024, and was reduced compared to a net loss of $151.6 million, or $0.51 per share basic and diluted, for the full year 2023. GAAP net income was $14.7 million, or $0.05 per share basic and diluted, for the fourth quarter 2024, compared to a net loss of $33.8 million, or $0.11 per share basic and diluted, for the fourth quarter 2023. The company anticipates achieving positive GAAP net income during H2 2025.
    • Non-GAAP net income2,3 was $73.9 million, or $0.24 per share, for the full year 2024, compared to a non-GAAP net loss of $38.5 million, or $0.13 per share basic and diluted, for the full year 2023. Non-GAAP net income was $29.2 million, or $0.10 per share basic and $0.09 per share diluted, for the fourth quarter 2024, compared to a net income of $2.6 million, or $0.01 per share basic and diluted, for the fourth quarter 2023.
    • Cash, cash equivalents, and marketable securities totaled $249.9 million at December 31, 2024, compared to $249.8 million at September 30, 2024 and $286.2 million at December 31, 2023.

    2025 Financial Guidance

    To advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:

    Total Revenue Growth117% to 24%
    Galafold Revenue Growth110% to 15%
    Pombiliti + Opfolda Growth165% to 85%
    Gross MarginMid 80%
    Non-GAAP Operating Expenses4$350M to $370M
    GAAP Net IncomePositive during H2 2025

    1 In order to illustrate underlying performance, Amicus discusses its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates had remained unchanged from those used in the comparative period.

    2 Full reconciliation of GAAP results to the Company's non-GAAP adjusted measures for all reporting periods appear in the tables to this press release.

    3 Amicus defines non-GAAP Net (Loss) Income as GAAP Net (Loss) Income excluding the impact of share-based compensation expense, changes in fair value of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition related income (expense), loss on extinguishment of debt, restructuring charges and income taxes.

    4 A reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to high variability, complexity, and low visibility as to the items that would be excluded from the GAAP measure.

    Conference Call and Webcast

    Amicus Therapeutics will host a conference call and audio webcast today, February 19, 2025, at 8:30 a.m. ET to discuss the full-year 2024 financial results and corporate updates. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN number to access the event.

    A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call. An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

    About Galafold 

    Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body's own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of people living with Fabry disease may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in more than 40 countries around the world, including the U.S., EU, U.K., and Japan.

    U.S. INDICATIONS AND USAGE

    Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

    This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

    U.S. IMPORTANT SAFETY INFORMATION

    ADVERSE REACTIONS: The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia. USE IN SPECIFIC POPULATIONS: There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus. It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition. Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis. The safety and effectiveness of Galafold have not been established in pediatric patients. To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf.

    About Pombiliti + Opfolda

    Pombiliti + Opfolda, is a two-component therapy that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that's designed to reduce loss of enzyme activity in the blood.

    U.S. INDICATIONS AND USAGE

    POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).

    SAFETY INFORMATION

    HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS: Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, POMBILITI should be discontinued immediately and appropriate medical treatment should be initiated. INFUSION-ASSOCIATED REACTIONS (IARs): If severe IARs occur, immediately discontinue POMBILITI and initiate appropriate medical treatment. RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS: Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function, may be at risk of serious exacerbation of their cardiac or respiratory status during POMBILITI infusion. See PI for complete Boxed Warning. CONTRAINDICATION: POMBILITI in combination with Opfolda is contraindicated in pregnancy. EMBRYO-FETAL TOXICITY: May cause embryo-fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for at least 60 days after the last dose. Adverse Reactions: Most common adverse reactions ≥ 5% are headache, diarrhea, fatigue, nausea, abdominal pain, and pyrexia. Please see full PRESCRIBING INFORMATION, including BOXED WARNING, for POMBILITI (cipaglucosidase alfa-atga) LINK and full PRESCRIBING INFORMATION for OPFOLDA (miglustat) LINK.

    About Amicus Therapeutics

    Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company's website at www.amicusrx.com, and follow on X and LinkedIn.

    Non-GAAP Financial Measures

    In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We use these non-GAAP measures as key performance measures for the purpose of evaluating operational performance and cash requirements internally. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. When we provide our expectation for non-GAAP operating expenses and profitability on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.

    Forward Looking Statement

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities and pricing and reimbursement authorities, are based on current information. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that required regulatory inspections may be delayed or not be successful and delay or prevent product approval; the potential that we may not be successful in negotiations with pricing and reimbursement authorities; the potential that we may not be successful in commercializing Galafold and/or Pombiliti and Opfolda in Europe, the UK, the US and other geographies; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies, the manufacturing, and commercialization of our products. With respect to statements regarding corporate financial guidance and financial goals and the expected attainment of such goals and projections of the Company's revenue, non-GAAP profitability and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2024 to be filed today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

    CONTACT:

    Investors:

    Amicus Therapeutics

    Andrew Faughnan

    Vice President, Investor Relations

    [email protected]

    (609) 662-3809

    Media:

    Amicus Therapeutics

    Diana Moore

    Head of Global Corporate Affairs and Communications

    [email protected]

    (609) 662-5079

    FOLD-G

     
    TABLE 1
     
    Amicus Therapeutics, Inc.

    Consolidated Statements of Operations

    (in thousands, except share and per share amounts)
      
     Years ended December 31,
      2024   2023   2022 
    Net product sales$528,295  $399,356  $329,233 
    Cost of goods sold 52,943   37,326   38,599 
    Gross profit 475,352   362,030   290,634 
    Operating expenses:     
    Research and development 109,362   152,381   276,677 
    Selling, general, and administrative 323,379   275,270   213,041 
    Changes in fair value of contingent consideration payable —   2,583   1,078 
    Loss on impairment of assets —   1,134   6,616 
    Restructuring charges 9,188   —   — 
    Depreciation and amortization 8,547   7,873   5,342 
    Total operating expenses 450,476   439,241   502,754 
    Income (loss) from operations 24,876   (77,211)  (212,120)
    Other (expense) income:     
    Interest income 5,407   7,078   3,024 
    Interest expense (49,598)  (50,149)  (37,119)
    Loss on extinguishment of debt —   (13,933)  — 
    Other (expense) income (9,441)  (15,886)  4,176 
    Loss before income tax (28,756)  (150,101)  (242,039)
    Income tax (expense) benefit (27,350)  (1,483)  5,471 
    Net loss attributable to common stockholders$(56,106) $(151,584) $(236,568)
    Net loss attributable to common stockholders per common share — basic and diluted$(0.18) $(0.51) $(0.82)
    Weighted-average common shares outstanding — basic and diluted 304,380,502   295,164,515   289,057,198 



    TABLE 2
     
    Amicus Therapeutics, Inc.

    Consolidated Balance Sheets

    (in thousands, except share and per share amounts)
     
     December 31,
      2024   2023 
    Assets   
    Current assets:   
    Cash and cash equivalents$213,752  $246,994 
    Investments in marketable securities 36,194   39,206 
    Accounts receivable 101,099   87,632 
    Inventories 118,782   59,696 
    Prepaid expenses and other current assets 34,909   49,533 
    Total current assets 504,736   483,061 
    Operating lease right-of-use assets, net 22,278   26,312 
    Property and equipment, less accumulated depreciation of $28,775 and $25,429 at December 31, 2024 and 2023, respectively 29,383   31,667 
    Intangible assets, less accumulated amortization of $5,802 and $2,510 at December 31, 2024 and December 31, 2023, respectively 17,198   20,490 
    Goodwill 197,797   197,797 
    Other non-current assets 13,641   18,553 
    Total Assets$785,033  $777,880 
    Liabilities and Stockholders' Equity   
    Current liabilities:   
    Accounts payable$12,947  $15,120 
    Accrued expenses and other current liabilities 127,300   144,245 
    Operating lease liabilities 8,455   8,324 
    Total current liabilities 148,702   167,689 
    Long-term debt 390,111   387,858 
    Operating lease liabilities 45,078   48,877 
    Other non-current liabilities 7,097   13,282 
    Total liabilities 590,988   617,706 
    Commitments and contingencies   
    Stockholders' equity:   
    Common stock, $0.01 par value, 500,000,000 shares authorized, 299,041,653 and 293,594,209 shares issued and outstanding at December 31, 2024 and 2023, respectively 2,944   2,918 
    Additional paid-in capital 2,926,115   2,836,018 
    Accumulated other comprehensive gain (loss):   
    Foreign currency translation adjustment 5,302   5,429 
    Unrealized loss on available-for-sale securities (207)  (188)
    Warrants 71   71 
    Accumulated deficit (2,740,180)  (2,684,074)
    Total stockholders' equity 194,045   160,174 
    Total Liabilities and Stockholders' Equity$785,033  $777,880 



    TABLE 3
     
    Amicus Therapeutics, Inc.

    Reconciliation of Non-GAAP Financial Measures

    (in thousands)

    (Unaudited)
     
      Years Ended December 31,
       2024  2023  2022
    Total GAAP operating expenses $450,476 $439,241 $502,754
    Research and development:      
    Share-based compensation  15,969  21,469  25,089
    Selling, general and administrative:      
    Share-based compensation  68,936  64,608  51,423
    Loss on impairment of assets  —  1,134  6,616
    Restructuring charge  9,188  —  —
    Changes in fair value of contingent consideration payable   —  2,583  1,078
    Depreciation and amortization  8,547  7,873  5,342
    Total Non-GAAP operating expense adjustments   102,640  97,667  89,548
    Total Non-GAAP operating expenses $347,836 $341,574 $413,206



    TABLE 4
     
    Amicus Therapeutics, Inc.

    Reconciliation of Non-GAAP Financial Measures

    (in thousands, except share and per share amounts)

    (Unaudited)
     
      Three Months Ended

    December 31,
     Years Ended

    December 31,
       2024   2023   2024   2023 
             
    GAAP net income (loss) $ 14,739  $    (33,843) $    (56,106) $    (151,584)
    Share-based compensation  19,217   18,095   84,905   86,077 
    Loss on impairment of assets  —   —   —   1,134 
    Changes in fair value of contingent consideration payable  —   —   —   2,583 
    Depreciation and amortization  2,041   2,182   8,547   7,873 
    Loss on extinguishment of debt  —   13,933   —   13,933 
    Restructuring charges  —   —   9,188   — 
    Income tax (benefit) expense  (6,805)  2,183   27,350   1,483 
    Non-GAAP net income (loss) $29,192  $2,550  $73,884  $(38,501)
             
    Non-GAAP net income (loss) attributable to common stockholders per common share — basic $0.10  $0.01  $0.24  $(0.13)
    Non-GAAP net income (loss) attributable to common stockholders per common share — diluted $0.09  $0.01  $0.24  $(0.13)
    Weighted-average common shares outstanding — basic  306,136,125   300,648,503   304,380,502   295,164,515 
    Weighted-average common shares outstanding — diluted  310,146,355   306,787,370   308,463,764   295,164,515 


    Primary Logo

    Get the next $FOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    2/24/2022$16.00 → $14.00Outperform
    SVB Leerink
    More analyst ratings

    $FOLD
    Leadership Updates

    Live Leadership Updates

    See more
    • Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

      Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

      8/21/23 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

      PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

      6/14/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

      Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

      5/6/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

      PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve. In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured. In PROPEL, 77% of patients (n=95) received enzyme replacement therapy (ERT) with alglucosidase alfa before study entry, with a median ERT duration of 7.4 years. In this new

      6/3/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

      PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at 11:40 a.m. ETGoldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL, on Tuesday, June 10, 2025, at 2:00 p.m. ET A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) is a global, patient

      5/30/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

      PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m. P.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordi

      5/7/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.

      SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      5/15/25 9:30:38 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amicus Therapeutics Inc.

      10-Q - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      5/1/25 4:02:46 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      5/1/25 7:00:45 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:00:58 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Amicus Therapeutics Inc.

      SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 11:37:23 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:31:54 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Campbell Bradley L covered exercise/tax liability with 13,375 shares, decreasing direct ownership by 1% to 1,137,282 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      3/18/25 5:56:44 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Campbell Bradley L exercised 400 shares at a strike of $9.03 and sold $4,000 worth of shares (400 units at $10.00) (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      2/21/25 7:27:08 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Prout Samantha was granted 27,416 shares and covered exercise/tax liability with 13,500 shares, increasing direct ownership by 15% to 109,441 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      2/13/25 5:22:50 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Financials

    Live finance-specific insights

    See more
    • Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

      1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and c

      5/1/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

      PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com

      4/21/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

      2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. "We closed 2024 beating expectations with exceptional revenue growth of 33 percent. With our portfolio and global rare disease capabilities, we have a clear path to deliver cont

      2/19/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amicus Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Amicus Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $17.00 previously

      12/13/24 7:53:22 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Amicus Therapeutics with a new price target

      Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00

      9/6/24 7:39:36 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Amicus Therapeutics with a new price target

      Wells Fargo initiated coverage of Amicus Therapeutics with a rating of Overweight and set a new price target of $18.00

      5/30/24 7:51:51 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care